Introduction to Olaparib manufacturer and original research information

Olaparib (Olaparib) is a PARP (polyADPribose polymerase) inhibitor. It is mainly used to treat various solid tumors such as ovarian cancer, breast cancer, prostate cancer and pancreatic cancer carrying BRCA mutations. The drug induces tumor cell apoptosis by inhibiting the DNA repair pathway of tumor cells and is one of the important targeted drugs for precision therapy. Since its launch, olaparib has been widely used in many countries and regions around the world, significantly improving the progression-free survival and quality of life of some advanced patients.

The original manufacturer of Lynparza is jointly developed by AstraZeneca (AstraZeneca) and Merck (Merck & Co., Inc.). The drug was originally developed by AstraZeneca and was first approved for marketing in the EU in 2014. Later, it was approved by the US FDA at the end of 2014, becoming the world's first PARP inhibitor to be marketed. In 2017, AstraZeneca and Merck of the United States reached a strategic cooperation to jointly promote the development, production and sales of Lynparza in the global market, further accelerating the layout of indication expansion, production capacity and supply system.

At present, AstraZeneca is responsible for the global production and supply of Lynparza's original drug, and it is marketed globally under the trade name Lynparza. The drug has production and packaging bases in Europe, the United States and many Asian countries to ensure stable global supply. In addition to the original drug, some countries and regions have successively approved the marketing of generic drugs of Lynparza, including some companies in India and China. These generic drugs need to undergo strict bioequivalence verification in terms of clinical efficacy and quality, and are relatively more affordable. However, the global market is still dominated by original drugs.

In China, Lynparza was introduced by AstraZeneca and has been approved for marketing by the National Food and Drug Administration (NMPA) for the treatment of ovarian cancer, breast cancer and prostate cancer with specific BRCA mutations. The versions sold in China are all original drugs and have been included in the national medical insurance catalog. The prices of some specifications have been significantly reduced after medical insurance reimbursement, improving patient accessibility. At the same time, many domestic pharmaceutical companies are promoting the registration and production of generic olaparib drugs, which is expected to further enrich market supply channels and reduce patients' medication burden in the future.

Reference link:https://www.drugs.com